Currently out of the existing stock ratings of Simos Simeonidis, 37 are a BUY (62.71%), 22 are a HOLD (37.29%).

Simos Simeonidis

Work Performance Price Targets & Ratings Chart

Analyst Simos Simeonidis, carries an average stock price target met ratio of 73.33% that have a potential upside of 44.69% achieved within 402 days. Previously, Simos Simeonidis worked at RBC.

Simos Simeonidis’s has documented 96 price targets and ratings displayed on 11 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on PBYI, Puma Biotechnology at 06-Jun-2017.

Wall Street Analyst Simos Simeonidis

Analyst best performing recommendations are on DVAX (DYNAVAX TECHNOLOGIES).
The best stock recommendation documented was for DVAX (DYNAVAX TECHNOLOGIES) at 4/27/2016. The price target of $17 was fulfilled within 2 days with a profit of $1.53 (8.26%) receiving and performance score of 41.28.

Average potential price target upside

of $53.28 (156.12%) on SRPT (SAREPTA THERAPEUTICS).
of $22.63 (25.77%) on INCY (YTE).
of $9.25 (28.69%) on PBYI (PUMA BIOTECHNOLOGY).

ALXN Alexion Pharmaceuticals DVAX Dynavax Technologies IMGN ImmunoGen INCY yte OREX Orexigen Therapeutics PBYI Puma Biotechnology SRPT Sarepta Therapeutics VVUS VIVUS ZFGN Zafgen PTCT PTC Therapeutics LRMR Larimar Therapeutics

Show more stocks

Analyst name

Rating

Rating initiation date

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score